GHRH(1-44) analog
N-terminal hexenoyl — DPP-IV resistant.
FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from peer-reviewed literature for educational reference.
Secretagogue Peptide
Tesamorelin
- EGRIFTA
- TH9507
CAS: 218949-48-5
A 44-amino-acid stabilized GHRH analog studied for pituitary GH secretion and visceral adipose tissue research in clinical models.
CoA available on request
- Free shipment protection
- Free shipping on $250+
- Damage protection
- 256-bit SSL checkout
Physiologic GH release
Studied in visceral adiposity research.
99%+ identity purity
HPLC + MS verified per batch. CoA included.
What Is Tesamorelin?
Tesamorelin is a GHRH(1-44) analog with a trans-3-hexenoyl modification at the N-terminus that confers resistance to DPP-IV cleavage. It binds GHRH receptors on pituitary somatotrophs, producing physiologic GH pulses. Studied in HIV-associated visceral adiposity, NAFLD, and cognitive aging research.
Technical specifications
Type
Synthetic GHRH analog
Formula
C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight
5135.8 g/mol
CAS number
218949-48-5
Appearance
White lyophilized powder
Identity purity
≥ 99% (HPLC + MS)
Peer-reviewed research
- JAMAEffects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
- N Engl J MedEffect of tesamorelin on visceral adipose tissue, body composition, and metabolic profile in HIV-infected patients with lipodystrophy
- Lancet HIVEffects of tesamorelin on non-alcoholic fatty liver disease in HIV
Frequently researched together
IMPORTANT RESEARCH NOTICE
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.